What is the 13F Pro Quality Score for AMLX?

13F Pro ranks Amylyx Pharmaceuticals, Inc. (AMLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMLX's current score at https://13fpro.ai/company/AMLX (free sign-up required for the full ranking).

Which hedge funds own the most AMLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AMLX include FMR, BlackRock,, PERCEPTIVE ADVISORS. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AMLX as soon as new 13F filings post.

Where does 13F Pro source AMLX data?

All Amylyx Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Amylyx Pharmaceuticals, Inc. files with the SEC under CIK 1658551. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMLX in?

Amylyx Pharmaceuticals, Inc. (AMLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMLX research updated on 13F Pro?

AMLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Amylyx Pharmaceuticals, Inc.(AMLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1658551 AMLX stock profile & AI dashboard →

13F Pro Quality Score

8.7/100

Rank #2,731 of 2,753 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

1.5/100

Profitability

6.0/100

Balance Sheet

1.3/100

Earnings Quality

8.6/100

Free Cash Flow

5.1/100

Institutional Flow

28.6/100

Revenue Scale

16.8/100

Dilution Risk

4.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AMLX Scores 9/100

exact factor attribution · 2026-03-02

AMLX's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings growth

-1.0 pts

30th pct

Institutional flow

-1.1 pts

29th pct

Shareholder dilution

-2.3 pts

5th pct

Earnings quality

-4.1 pts

9th pct

Capital efficiency

-4.9 pts

1th pct

Scale

-5.0 pts

17th pct

Profitability

-6.6 pts

6th pct

Free cash flow

-6.7 pts

5th pct

Revenue growth

-9.7 pts

2th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AMLX Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Amylyx Pharmaceuticals, Inc. (AMLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMLX at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,731 of 2,753 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.3) and revenue growth (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AMLX by reported 13-F value include FMR, BlackRock, PERCEPTIVE ADVISORS, based on the most recent SEC filings. AMLX trades on the Nasdaq exchange and files with the SEC under CIK 1658551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amylyx Pharmaceuticals, Inc. directly from SEC EDGAR. Amylyx Pharmaceuticals, Inc.'s 13F Pro composite quality score has ranged between 7 and 41 since 2024, currently 8.7 — a declining long-term trajectory across 13 quarterly and live scoring snapshots.

Net Income

Q2 2026

$-43.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-100.0% YoY

$0.00FY 2025

FY22 $22.2MFY23 $380.8MFY24 $87.4MFY25 $0.00

Net Income

+52.0% YoY

$-144.7MFY 2025

FY22 $-198.4MFY23 $49.3MFY24 $-301.7MFY25 $-144.7M

Operating Income

+51.3% YoY

$-153.3MFY 2025

FY22 $-201.3MFY23 $38.8MFY24 $-314.7MFY25 $-153.3M

EPS (Diluted)

+65.5% YoY

$-1.53FY 2025

FY22 $-3.39FY23 $0.70FY24 $-4.43FY25 $-1.53

Total Assets

+71.8% YoY

$332.6MFY 2025

FY22 $391.5MFY23 $517.5MFY24 $193.6MFY25 $332.6M

Op. Cash Flow

+26.4% YoY

$-123.3MFY 2025

FY22 $-179.9MFY23 $11.9MFY24 $-167.6MFY25 $-123.3M

Free Cash Flow

+26.4% YoY

$-123.5MFY 2025

FY22 $-182.4MFY23 $10.7MFY24 $-167.8MFY25 $-123.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$87.4M -77.1%	$380.8M +1612.9%	$22.2M +7700.0%	$285.0K	—
Net Income	$-144.7M +52.0%	$-301.7M -712.4%	$49.3M +124.8%	$-198.4M -125.6%	$-87.9M	—
Operating Income	$-153.3M +51.3%	$-314.7M -911.1%	$38.8M +119.3%	$-201.3M -143.5%	$-82.7M	—
EPS (Diluted)	$-1.53 +65.5%	$-4.43 -732.9%	$0.70 +120.6%	$-3.39 +74.6%	$-13.35	—
Total Assets	$332.6M +71.8%	$193.6M -62.6%	$517.5M +32.2%	$391.5M +270.6%	$105.6M	—
Operating Cash Flow	$-123.3M +26.4%	$-167.6M -1506.6%	$11.9M +106.6%	$-179.9M -140.5%	$-74.8M	—
Free Cash Flow	$-123.5M +26.4%	$-167.8M -1671.5%	$10.7M +105.9%	$-182.4M -142.7%	$-75.2M	—

Get alerted when AMLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Amylyx Pharmaceuticals, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMLX

FMR LLC
$300.4M16,727,909 sh
BlackRock, Inc.
$158.5M8,827,085 sh
PERCEPTIVE ADVISORS LLC
$149.7M8,334,882 sh
TCG Crossover Management, LLC
$112.1M6,243,812 sh
Commodore Capital LP
$101.5M5,650,000 sh
Jupiter Topco LLC
$94.0M5,236,102 sh
Saturn V Capital Management LP
$83.0M4,624,101 sh
VANGUARD CAPITAL MANAGEMENT LLC
$75.9M4,224,224 sh
MORGAN STANLEY
$56.2M3,130,808 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$54.5M3,036,970 sh

Fund	Value	Shares
FMR LLC	$300.4M	16,727,909
BlackRock, Inc.	$158.5M	8,827,085
PERCEPTIVE ADVISORS LLC	$149.7M	8,334,882
TCG Crossover Management, LLC	$112.1M	6,243,812
Commodore Capital LP	$101.5M	5,650,000
Jupiter Topco LLC	$94.0M	5,236,102
Saturn V Capital Management LP	$83.0M	4,624,101
VANGUARD CAPITAL MANAGEMENT LLC	$75.9M	4,224,224
MORGAN STANLEY	$56.2M	3,130,808
DRIEHAUS CAPITAL MANAGEMENT LLC	$54.5M	3,036,970

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMLX on your watchlist

Track score changes the day Amylyx Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMLX a good stock to buy?

13F Pro's AI-powered analysis of Amylyx Pharmaceuticals, Inc. (AMLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMLX are available on the AMLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AMLX is classified as a mid company.

Which hedge funds own AMLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Amylyx Pharmaceuticals, Inc.'s investment landscape.